The new work, led by Michelle M. Maurin and Siddabasave Gowda B. Gowda with senior author Timothy J. Yeatman, began with a straightforward hypothesis: that the sphingosine-1-phosphate-to-ceramide ratio matters more in the tumor microenvironment than in the malignant epithelial cells that have dominated the literature since the 1990s. To test it, the team performed quantitative liquid chromatography–tandem mass spectrometry, a gold-standard technique for measuring lipid species with high precision, on 480 resected primary colorectal tumors and 94 metastatic colorectal cancer specimens. The comparison revealed a striking biochemical shift. Metastatic lesions were enriched in sphingosine-1-phosphate and its close relative sphinganine-1-phosphate, while a specific ceramide species, ceramide 24:1, was depleted. In other words, the metastatic lipid landscape had tipped decisively toward the pro-survival, pro-signaling arm of the pathway.

Lipid measurements alone could not say which cells were responsible, so the investigators layered on gene-expression analysis at remarkable scale. Quantitative real-time PCR confirmed that enzymes that synthesize sphingosine-1-phosphate and sphinganine-1-phosphate, particularly sphingosine kinase 1, or SPHK1, were elevated in metastatic colorectal cancer compared with primary disease, along with the lipid’s receptors S1PR3, S1PR4 and S1PR5. The team then mined a large gene-expression dataset of 2,373 colorectal cancer samples, combining clinical outcomes with molecular profiles, and applied CIBERSORT, a computational method that estimates the relative abundance of different cell types from bulk RNA transcripts. Public single-cell RNA-sequencing data provided an independent check at single-cell resolution.

The cellular attribution was unambiguous. SPHK1 and its receptor S1PR3 were expressed predominantly in stromal cells and immune cells within the tumor microenvironment, whereas the related kinase SPHK2 predominated in epithelial tumor cells. High-definition spatial transcriptomics added a geographic dimension, showing where in the tumor architecture these programs were active, and immunofluorescence imaging of patient sections revealed SPHK1 staining co-localizing with CD163, a marker of M2 macrophages, in the stroma surrounding tumor nests. The kinase signal sat outside the keratin-positive cancer cells, in the very neighborhoods where immune suppression is thought to be manufactured.

From these data the researchers distilled a three-gene sphingosine-1-phosphate signature and asked what it predicted. The answer was grim but coherent. High signature scores were associated with stromal enrichment, with infiltration by myeloid-derived suppressor cells and M2 macrophages, with advanced stage, with nodal involvement and with poor survival. Perhaps most consequentially, the signature showed weak to negative correlations with validated gene-expression scores that predict response to checkpoint inhibitor therapy, the immunotherapies that have transformed treatment for many cancers but delivered only modest benefits in colorectal cancer, particularly microsatellite-stable disease.

That last finding carries the study’s translational punch. Checkpoint inhibitors work by releasing the brakes on T cells, but they depend on a tumor microenvironment that still permits T cells to function. A lipid program that enriches the stroma with suppressive myeloid cells and M2 macrophages is precisely the kind of barrier that renders such therapies ineffective. The sphingosine-1-phosphate axis, the authors conclude, is not merely a bystander correlate of aggressive disease; it is plausibly a mechanistic contributor to the immunosuppressive state that shields metastatic colorectal cancer from immune attack.

The laboratory experiments in the study reinforce that interpretation. In vitro, the team cultured human macrophages under M1, classically inflammatory, or M2, alternatively activated, conditions and examined the effects of their conditioned media on primary T cells. Flow cytometry measured T cell phenotypes, proliferation, activation markers such as interferon-gamma and CD107a granule mobilization, and cytotoxic killing of tumor target cells. Pharmacological inhibition of sphingosine kinase activity with the SPHK1 inhibitor PF-543 and the S1PR3 antagonist CAY10444 was used to probe whether blocking the axis could rescue T cell function in these co-culture systems, alongside assays of T cell migration toward macrophage-conditioned media.

Conceptually, the study reframes a thirty-year-old model. The original rheostat placed the sphingosine-1-phosphate/ceramide balance inside the tumor cell, where rising sphingosine-1-phosphate was read as a cell-autonomous survival advantage. The new data reposition the dial in the tumor’s supporting ecosystem: stromal cells and myeloid immune cells that generate sphingosine-1-phosphate, signal through receptors such as S1PR3, and thereby help construct a microenvironment hostile to cytotoxic immunity. This stromal-immune program links lipid metabolism to inflammation and immunosuppression simultaneously, explaining why the same pathway that once looked like a survival factor for cancer cells now looks like a communication network between the tumor and its immune entourage.

The clinical implications are significant for a disease with a large unmet need. Colorectal cancer remains a leading cause of cancer death worldwide, and metastatic disease in particular responds poorly to immunotherapy outside the small microsatellite-instability-high subset. If the sphingosine-1-phosphate/ceramide imbalance helps maintain that resistance, then therapeutic strategies aimed at rebalancing the ratio, whether by inhibiting SPHK1 in stromal and myeloid cells, blocking S1PR3 signaling, or otherwise reprogramming the suppressive microenvironment, could sensitize tumors to checkpoint blockade. The three-gene signature itself may also serve as a biomarker, identifying patients whose tumors harbor the suppressive lipid program and who might be candidates for combination approaches.

Cautions remain, as they must in any study moving from association toward mechanism. The human data are largely correlative, drawn from resected specimens and retrospective datasets, and the authors note that the published version was shared early as accepted peer-reviewed research. Sphingolipid biology is intricate, with dozens of ceramide species, multiple kinases and five receptors whose roles differ by context, and the field has previously seen promising lipid-targeted strategies falter in translation. Still, the scale of the analysis, spanning targeted lipidomics in hundreds of tumors, a 2,373-sample expression cohort, spatial transcriptomics, single-cell data and functional co-culture assays, gives the reframing unusual weight. The sphingosine rheostat, first sketched as a switch inside the cancer cell, now appears to be a dial held jointly by the stroma and the immune system, and turning it back may be a route to making metastatic colorectal cancer visible to immunotherapy.

Subject of Research: The sphingosine-1-phosphate/ceramide rheostat as a stromal-immune program driving immune suppression in metastatic colorectal cancer

Article Title: Re-defining the sphingosine rheostat as a stromal-immune program associated with immune suppression in metastatic colorectal cancer

Article References: Maurin, M. M., Gowda, S. G. B., Eksioglu, E. A., Nebozhyn, M. V., Razabdouski, T., Gowda, D., Adapa, S. R., Jiang, R. H. Y., Wang, H., Soundararajan, R., Carr, M., Sundaraswamy, P. M., Alden, A. J., Martinez, C., Bennett, R. D., Chudzinski, A. P., Karachristos, A., Nywening, T. M., Cavallaro, P. M., … Yeatman, T. J. (2026). Re-defining the sphingosine rheostat as a stromal-immune program associated with immune suppression in metastatic colorectal cancer. Journal of Experimental & Clinical Cancer Research. https://doi.org/10.1186/s13046-026-03832-1

Image Credits: AI Generated

DOI: 10.1186/s13046-026-03832-1

Keywords: sphingosine-1-phosphate, ceramide, sphingosine rheostat, metastatic colorectal cancer, tumor microenvironment, SPHK1, S1PR3, M2 macrophages, myeloid-derived suppressor cells, immunosuppression, checkpoint inhibitor resistance, lipidomics

The research team, led by Gaoquan Zheng, Dianqing Li, and colleagues, set out to test whether a deliberate local pH signal built into the implant interface could guide neutrophil behavior and strengthen host antibacterial defense without adding any exogenous bactericidal agent. Neutrophils are among the first innate immune cells recruited to infected sites, and beyond phagocytosis and degranulation they can release neutrophil extracellular traps, or NETs, which are extracellular chromatin-based networks that capture pathogens and limit their spread. Prior work had hinted that extracellular pH regulates this process: bicarbonate-rich pancreatic fluid has been shown to promote PADI4-dependent aggregated NET formation, a high bicarbonate-to-CO2 ratio and moderately alkaline pH favor NET release, and extracellular acidosis suppresses ROS-dependent NETosis. What remained poorly understood was how such a physicochemical cue is converted into functional changes inside the neutrophil, and whether it could be harnessed at a biomaterial surface.

To create the alkaline interface, the researchers subjected titanium plates to a hydrothermal reaction in a mixed sodium hydroxide and hydrogen peroxide solution at 80 degrees Celsius for 24 hours, followed by hydrochloric acid-mediated ion exchange to remove excess sodium-containing alkaline species and a thermal treatment ramping to 450 degrees Celsius. The resulting material, designated Ti-A, developed a uniform nanoscale porous architecture visible by scanning electron microscopy, in contrast to the relatively smooth pristine titanium surface. X-ray diffraction confirmed a mixed anatase and rutile TiO2 crystalline structure, and X-ray photoelectron spectroscopy detected a distinct sodium signal reflecting the incorporation of sodium-related species during alkali treatment. Critically, pH measurements taken approximately two millimeters above the surface showed that Ti-A maintained a local pH of roughly 7.88 in ultrapure water and, importantly, remained within a mildly alkaline range of about 7.49 to 7.78 even under physiological buffering conditions in PBS and cell culture medium over 48 hours.

The team then verified that this modified surface was compatible with the cells that matter. Rat bone marrow mesenchymal stem cells cultured on Ti-A retained well-organized F-actin cytoskeletons and intact nuclear morphology, with metabolic activity remaining approximately 92 percent of that observed on pristine titanium despite a modest but significant reduction. Neutrophils exposed to Ti-A for six hours retained roughly 89 percent of their CCK-8 metabolic signal, indicating that the interface did not cause extensive loss of neutrophil viability during the NET-induction period. With biocompatibility established, the researchers turned to the central question of whether Ti-A could trigger bona fide NET formation rather than nonspecific DNA leakage. SYTOX Green staining revealed more extracellular DNA-positive structures on Ti-A than on pristine Ti, and DNase I treatment markedly reduced these networks, confirming their dependence on a DNA scaffold.

Further molecular evidence strengthened the case. Ti-A markedly increased signals of citrullinated histone H3, a chromatin modification closely associated with NET formation, which colocalized with extracellular chromatin regions. Enzyme-linked immunosorbent assays showed higher levels of MPO-DNA complexes in the Ti-A group, indicating co-release of extracellular chromatin with neutrophil granule proteins, a biochemical hallmark of genuine NETs. When neutrophils and S. aureus were co-incubated on the surfaces for six hours, Ti-A achieved an antibacterial rate of approximately 86.67 percent compared with 47.50 percent on pristine titanium. Even without neutrophils present, Ti-A reduced bacterial survival, demonstrating intrinsic surface antibacterial activity, but the addition of neutrophils revealed a substantial host-mediated enhancement on top of that direct effect.

To dissect the mechanism, the researchers applied two pharmacological tools. DNase I, which degrades the extracellular DNA backbone of NETs, caused colony formation on Ti-A to rise sharply and the antibacterial rate to fall to a level close to that of Ti-A alone, indicating that NET-associated extracellular DNA structures were a major contributor to the enhanced killing. Cytochalasin D, which inhibits actin-dependent phagocytosis, also reduced the antibacterial rate, but it remained higher than that of Ti-A alone, suggesting that phagocytosis contributed without fully accounting for the neutrophil-mediated advantage. Together, these experiments established that beyond directly restricting bacterial survival, the alkaline interface amplified neutrophil extracellular killing as the dominant antibacterial mechanism.

The deepest insight of the study came from untargeted metabolomic profiling of neutrophils stimulated on the two surfaces. Volcano plot analysis revealed 77 upregulated and 7 downregulated metabolites in the Ti-A group, with lipid metabolism dominating the differential profile. Sphingosine and N-palmitoyl-D-sphingosine were elevated and ranked among the most important metabolites distinguishing Ti-A-stimulated neutrophils from controls, while 6-phosphogluconic acid, a metabolite of the oxidative pentose phosphate pathway that supplies NADPH for reactive oxygen species generation, was also increased. KEGG enrichment analysis placed sphingolipid metabolism and sphingolipid signaling among the top enriched pathways. This metabolic signature pointed the investigators toward a specific signaling axis: sphingosine can be phosphorylated by sphingosine kinase 1, or SPHK1, to generate sphingosine-1-phosphate, which signals through receptors including S1PR2 and may engage calcium- and MAPK-related pathways linked to PAD4 activation, histone H3 citrullination, chromatin decondensation, and NET formation.

Subsequent molecular and pharmacological experiments supported this model. Neutrophils on Ti-A showed markedly stronger intracellular oxidative signals by DCFH-DA fluorescence and flow cytometry, and both SPHK1 and S1PR2 were significantly upregulated at the mRNA and protein levels. Notably, PMA, a standard positive NET-inducing stimulus, enhanced oxidative activity without inducing comparable SPHK1 or S1PR2 increases, indicating that this upregulation is not a generic consequence of NET induction but is more closely tied to the sphingolipid remodeling triggered by Ti-A. When the researchers blocked the pathway with PF-543, a selective SPHK1 inhibitor, or with DPI, which suppresses NADPH oxidase-derived ROS production, both the web-like extracellular DNA structures and the intracellular oxidative signal were significantly attenuated. Because neither inhibitor completely abolished NET formation, the authors conclude that the SPHK1-S1PR2/ROS axis makes a substantial contribution while operating alongside other signaling events initiated at the interface.

The strategy then faced its most demanding test in vivo. Titanium and Ti-A implants preloaded with S. aureus were inserted into femoral condyle defects in rats. At three days after surgery, fewer colonies were recovered from peri-implant bone tissues in the Ti-A group, accompanied by stronger Ly6G neutrophil staining, enhanced H3Cit signals indicating histone citrullination, and elevated SPHK1 and S1PR2 expression at the interface. At two months, bacterial burden remained significantly lower around Ti-A implants, and micro-CT reconstruction showed more newly formed bone with significantly higher bone volume fraction and bone mineral density. Histology revealed richer bone matrix and collagen deposition, stronger osteopontin staining, and milder inflammatory infiltration, while H&E staining of major organs showed no pathological damage, indicating no evident systemic toxicity.

Importantly, the modified interface did not trade immune-antibacterial activity for impaired osteogenic function. In vitro, Ti-A supported stronger alkaline phosphatase staining and activity, more extensive Alizarin Red S mineral deposition, and increased Runx2 and Col1a1 expression during osteogenic induction. The authors caution that the biological consequences of NET formation depend strongly on timing, magnitude, and clearance: early NETs can immobilize bacteria and assist macrophage-mediated killing, whereas persistent or excessive NETs may sustain inflammation and damage tissue. Their experiments did not track NET formation and clearance continuously, and serial measurements at intermediate time points will be needed to define how the response subsides as the interface shifts from infection control toward tissue repair. Nevertheless, the work positions mild interfacial alkalinity as a host-responsive design cue for anti-infective bone implants, offering a route to coordinate early infection control and subsequent bone regeneration that could hold particular translational value for patients facing infected bone defects where both problems must be solved concurrently.

Subject of Research: Mildly alkaline titanium implant interfaces regulating neutrophil sphingolipid immunometabolism and NET formation for antibacterial host defense and bone repair

Article Title: Interfacial mild alkalinity shapes Neutrophil immunometabolism through sphingolipid remodeling to enhance antibacterial host defense

Article References: Interfacial mild alkalinity shapes Neutrophil immunometabolism through sphingolipid remodeling to enhance antibacterial host defense. (n.d.). https://doi.org/10.1016/j.mtbio.2026.103691

Image Credits: AI Generated

DOI: 10.1016/j.mtbio.2026.103691

Keywords: neutrophils, neutrophil extracellular traps, implant-associated infection, titanium implant, interfacial pH, sphingolipid metabolism, SPHK1, S1PR2, reactive oxygen species, Staphylococcus aureus, osseointegration, bone regeneration